National Guideline Clearinghouse | American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis.

full-text ►
National Guideline Clearinghouse | American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis.

Guideline Title

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis.

 

Bibliographic Source(s)

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM, AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010 Nov-Dec;16(Suppl 3):1-37. [209 references] PubMed

Guideline Status

This is the current release of the guideline.
This guideline updates a previous version: Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003 Nov-Dec;9(6):544-64.

Endocr Pract. 2010 Nov-Dec;16 Suppl 3:1-37.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM; AACE Osteoporosis Task Force.

PMID:

21224201

[PubMed - indexed for MEDLINE]

American Association of Clinical Endocr... [Endocr Pract. 2010 Nov-Dec] - PubMed - NCBI

Related citations

• American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.[Endocr Pract. 2010]
  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

  Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, et al. Endocr Pract. 2010 Nov-Dec; 16(6):1016-9.
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.[Endocr Pract. 2011]
  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

  Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, American Association of Clinical Endocrinologists. Endocr Pract. 2011 Jul-Aug; 17 Suppl 4:1-44.
• Review [Current approaches to the diagnosis and treatment of postmenopausal osteoporosis].[Ter Arkh. 2009]
  Review [Current approaches to the diagnosis and treatment of postmenopausal osteoporosis].

  Baranova IA. Ter Arkh. 2009; 81(10):56-60.
• Review [Drug treatment of postmenopausal osteoporosis. What's New in 2006].[Presse Med. 2006]
  Review [Drug treatment of postmenopausal osteoporosis. What's New in 2006].

  Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S, Cortet B, Costagliola D, Diebolt V, Lacoin F, et al. Presse Med. 2006 Oct; 35(10 Pt 2):1529-39.
• Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?[Rheum Dis Clin North Am. 2011]
  Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?

  Laster AJ, Tanner SB. Rheum Dis Clin North Am. 2011 Aug; 37(3):323-36, v.

See reviews...See all...

Cited by 2 PubMed Central articles

• Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.[BMC Infect Dis. 2012]
  Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

  Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, et al. BMC Infect Dis. 2012 Feb 14; 12:38. Epub 2012 Feb 14.
• Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.[Drug Healthc Patient Saf. 2011]